VAG
TGTX icon

VisionPoint Advisory Group’s TG Therapeutics TGTX Stock Holding History

VisionPoint Advisory Group’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-75
Closed -$1.33K – 725
2024
Q2 		$1.33K Hold
75
– – ﹤0.01% 700
2024
Q1 		$1.14K Buy
+75
New +$1.2K ﹤0.01% 718

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VisionPoint Advisory Group's TGTX Position: Q3 2024 in Review

VisionPoint Advisory Group sold out of TG Therapeutics (TGTX) in Q3 2024, closing a stake of 75 shares — an estimated $1.33K sold.

VisionPoint Advisory Group first reported a position in TGTX in Q1 2024 and held it in 2 quarters. The position peaked at $1.33K in Q2 2024. 308 funds tracked by Wall St. Rank hold TGTX as of Q3 2024.

  • VisionPoint Advisory Group reported no remaining TG Therapeutics position as of Q3 2024 after selling out during the quarter.
  • VisionPoint Advisory Group sold 75 TG Therapeutics shares in Q3 2024, an estimated $1.33K.
  • VisionPoint Advisory Group first reported a position in TG Therapeutics in Q1 2024 and held it in 2 quarters.
  • VisionPoint Advisory Group's TG Therapeutics position peaked at $1.33K in Q2 2024.
  • 308 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2024.

Based on VisionPoint Advisory Group's 13F filing for Q3 2024, filed 15 Oct 2024.